



# BAFNA PHARMACEUTICALS LTD.,

REGD. OFFICE: "BAFNA TOWERS" 299, THAMBU CHETTY STREET, CHENNAI-600 001, INDIA.  
PHONE: +044-25267517/25270992/42677555, FAX: 91-44-25231264, mail: info@bafnapharma.com, website: www.bafnapharma.com

January 7, 2017 CIN: L24294TN1995PLC030698

Listing Department  
The Bombay Stock Exchange Limited  
P J Towers  
Dalal Street  
Mumbai – 400 001  
SCRIP CODE: 532989  
ISIN: INE 878I01014

Listing Department  
National Stock Exchange of India Limited  
Exchange Plaza, Bandra Kurla Complex  
Bandra (E)  
Mumbai – 400051  
SCRIP SYMBOL: BAFNAPHARM

Sub: Outcome of 160<sup>th</sup> (09/2016-17) Board Meeting

Dear Sir,

This is to inform you under Regulation 30 and any other Regulation of SEBI (Listing Obligation and Disclosure Requirement) Regulation, 2015 that a meeting of the Board of Directors of the Company was held on Saturday, 07<sup>th</sup> January, 2017 and the said meeting commenced at 12.00 P.M. and concluded at 01.45 P.M.

In the meeting, the following matters were decided by the Board:

Considered and decided to issue 80,00,000 share warrants on preferential basis to promoter and non-promoter group at such price as may be arrived at in accordance with SEBI (ICDR) Regulations, 2009, subject to the approval of the members of the Company through Postal Ballot by way of passing a special resolution under section 42 and 62 of the Companies Act, 2013 and other necessary approvals. It was further decided that the Company would notify through the newspapers the price of each equity share to be issued in lieu of Warrants calculated in accordance with Regulation 76(1) of Chapter VII of the SEBI ICDR Regulations on the basis of the Relevant Date for the benefit of the Members.

Thanking You,

Yours faithfully,

For BAFNA PHARMACEUTICALS LIMITED

Bafna Mahaveer Chand  
Managing Director  
(DIN: 01458211)